Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.

In addition to LX1032, Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

"This is an important study, designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers."

The Phase 2 clinical trial is designed as a four-week, randomi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 A Geisinger researcher on a personal ... Centers for Disease Control and Prevention (CDC) award recognizing ... concern. Joseph Boscarino , Ph.D. MPH, ... team of researchers nominated for the Centers for Disease ... for Data Methods and Study Design. "Hepatitis ...
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Sales Horizons, ... of its online sales skills training course ... skills. , MedTech clinical staff spend the majority of ... hospital, standalone medical center, or physician practice – providing ... But why stop there? Sales Horizons believes clinical staff ...
(Date:8/18/2014)... WASHINGTON , Aug. 18, 2014   Sterne, ... law firm in Washington, DC , ... Inter Partes Review (IPR) with the U.S. ... Inc., a subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI). ... co-owned, or licensed by Myriad Genetics, Inc. These patents ...
Breaking Biology Technology:Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... , , , , Multiporator , , , , ... Transfection Protocol , Protocol No. 4308 915.024 11/2001 , ... , , , , , ... line), , , ...
... , , , , , , Multiporator / Electroporator 2510 , , , ... , Transformation Protocol , Protocol No. 4308 915.512 ... , , , , , , ... , Cell type , ...
... , , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.022 11/1999 , ... , , , Cell line , ... Transfection with , Plasmid RSV/lacZ (in bidistilled H 2 O), ...
Cached Biology Technology:H73C11 2H73C11 3Escherichia coli DH5 2Escherichia coli DH5 3COS-7 2
(Date:8/20/2014)... A new gene therapy developed by researchers at ... shown to protect mice from a life-threatening heart condition ... new therapeutic avenue," said Yi Lai, Ph.D., the leading ... the MU School of Medicine,s Department of Molecular Microbiology ... we hope this could lead to a treatment for ...
(Date:8/20/2014)... researchers have developed methods for electronically manipulating the flight ... moths use to control those muscles. The work opens ... "biobots," for use in emergency response. , "In the ... control the movement of moths for use in applications ... Bozkurt, an assistant professor of electrical and computer engineering ...
(Date:8/20/2014)... and POINT ROBERTS, Washington , ... Play a Key Role in Addressing Security Concerns in the ... a global news source covering leading sectors including biometrics, issues ... market. Jason Peaslee , Managing Partner at ... and Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Research paves way for development of cyborg moth 'biobots' 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... Researchers at the University of Illinois at Chicago College ... on the nervous system to create the devastation of Huntington,s ... Nature Neuroscience online. The researchers were able to ... called JNK3, which is expressed only in neurons and, further, ...
... soil microbe that uses chemical warfare to fight off ... of its arsenal, researchers report, making use of an ... known to do: break a non-activated carbon-carbon bond in ... in the journal Nature , provides the first ...
... play a role in growth of some types of ... cancer development, say researchers from the Lombardi Comprehensive Cancer ... findings, presented at the annual meeting of the Endocrine ... this protein, known as Stat5a, may be different in ...
Cached Biology News:Huntington's disease deciphered 2Huntington's disease deciphered 3Researchers describe 'implausible' chemistry that produces herbicidal compound 2Dual role in breast tissue for a protein involved in leukemia 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... Source produces a powerful, stable output from 215-400 ... source are available, providing a wavelength range of ...
... and mitochondrial membrane potential. The mitochondrial permeability ... the initiation of cellular apoptosis. This process ... the electrochemical gradient across the mitochondrial membrane, ... membrane potential (YD). Loss of mitochondrial YD ...
Biology Products: